Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum: Measurement of the Sixth-Order Cumulant of Net-Proton Multiplicity Distributions in Au+Au Collisions at sqrt[s_{NN}]=27, 54.4, and 200 GeV at RHIC [Phys. Rev. Lett. 127, 262301 (2021)].

Physical review letters·2025
Same author

Effectiveness of quality improvement collaboratives in improving clinical processes and patient outcomes in stroke care.

British journal of neuroscience nursing·2024
Same author

Observation of Directed Flow of Hypernuclei _{Λ}^{3}H and _{Λ}^{4}H in sqrt[s_{NN}]=3  GeV Au+Au Collisions at RHIC.

Physical review letters·2023
Same author

Exploring the benefits of nature-based interventions in socio-economically deprived communities: a narrative review of the evidence to date.

Perspectives in public health·2023
Same author

Measurement of Sequential ϒ Suppression in Au+Au Collisions at sqrt[s_{NN}]=200  GeV with the STAR Experiment.

Physical review letters·2023
Same author

Beam Energy Dependence of Fifth- and Sixth-Order Net-Proton Number Fluctuations in Au+Au Collisions at RHIC.

Physical review letters·2023

Related Experiment Video

Updated: Mar 5, 2026

Mammosphere Formation Assay from Human Breast Cancer Tissues and Cell Lines
10:51

Mammosphere Formation Assay from Human Breast Cancer Tissues and Cell Lines

Published on: March 22, 2015

34.4K

Robotic Mammosphere Assay for High-Throughput Screening in Triple-Negative Breast Cancer.

P A Fitzpatrick1, N Akrap1, E M V Söderberg1

  • 11 Sahlgrenska Cancer Center, Göteborgs Universitet, Göteborg, Sweden.

SLAS Discovery : Advancing Life Sciences R & D
|March 28, 2017
PubMed
Summary

Researchers identified novel treatments for triple-negative breast cancer (TNBC) by screening FDA-approved drugs. Three compounds effectively targeted cancer stem cells, offering potential as new adjuvant therapies.

Keywords:
cancer and cancer drugscell-based assayshigh-content screeningstem cells

More Related Videos

Quantification of Self-renewal in Murine Mammosphere Cultures
07:40

Quantification of Self-renewal in Murine Mammosphere Cultures

Published on: November 26, 2019

6.8K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K

Related Experiment Videos

Last Updated: Mar 5, 2026

Mammosphere Formation Assay from Human Breast Cancer Tissues and Cell Lines
10:51

Mammosphere Formation Assay from Human Breast Cancer Tissues and Cell Lines

Published on: March 22, 2015

34.4K
Quantification of Self-renewal in Murine Mammosphere Cultures
07:40

Quantification of Self-renewal in Murine Mammosphere Cultures

Published on: November 26, 2019

6.8K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K

Area of Science:

  • Oncology
  • Biotechnology
  • Pharmacology

Background:

  • Triple-negative breast cancer (TNBC) is aggressive and lacks targeted therapies.
  • Cancer stem cells (CSCs) drive tumor recurrence and metastasis in TNBC.
  • Novel therapeutic strategies targeting CSCs are urgently needed.

Purpose of the Study:

  • To develop and validate a high-throughput screening (HTS) assay for identifying CSC-targeting agents in TNBC.
  • To screen FDA-approved drugs for their ability to modulate the CSC fraction in TNBC.
  • To identify potential novel adjuvant treatments for TNBC.

Main Methods:

  • Development of an HTS assay using mammosphere and anoikis resistance assays for functional readout.
  • Validation of the HTS assay against manual protocols and with positive controls (hypoxia, salinomycin).
  • Comparison of manual versus robotic procedures, showing no significant difference in results.
  • Screening of 989 FDA-approved drugs, followed by a focused screen of the antineoplastic subgroup.

Main Results:

  • The HTS assay demonstrated reliability and reproducibility, comparable between manual and robotic methods.
  • Three compounds were identified that significantly modulate the cancer stem cell fraction in MDA-MB-231 TNBC cells.
  • These compounds showed potential as stem cell-specific agents.

Conclusions:

  • A validated HTS platform can effectively identify CSC-targeting compounds in TNBC.
  • Specific FDA-approved drugs show promise as novel adjuvant therapies by targeting TNBC CSCs.
  • Further investigation into these compounds could lead to improved treatment strategies for TNBC.